XORTX Therapeutics Investor Relations Material

XORTX Therapeutics Inc is a Canada-based clinical-stage biopharmaceutical company focused on developing therapies for chronic kidney disease and other health conditions related to abnormal purine metabolism and uric acid imbalance. The company’s lead drug candidates aim to lower serum uric acid levels to prevent or slow the progression of kidney and cardiovascular diseases. XORTX conducts research and clinical trials to advance its proprietary formulations. The company is headquartered in Calgary, Alberta, and its shares are listed on the NASDAQ.